Electromed, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2017. The request references “2016 Q4,” but the supplied filing is the fiscal 2017 annual report, not a quarterly filing.
Business Context
Electromed develops, manufactures and sells airway-clearance products using High Frequency Chest Wall Oscillation technology. Its primary product is the SmartVest Airway Clearance System, sold through a direct-to-patient and provider model in home-care and institutional markets. The company also began distributing the Aerobika OPEP device in the U.S. home-care market in early calendar 2017.
In June 2017, Electromed launched SmartVest SQL with SmartVest Connect wireless therapy-management technology. Management expected to expand Connect availability to targeted adult pulmonary clinics during fiscal 2018.
Financial Performance and Liquidity
| Metric | FY2017 | FY2016 | Change |
|---|---|---|---|
| Net revenue | $25.861 million | $22.992 million | +12.5% |
| Home-care revenue | $23.387 million | $20.500 million | +14.1% |
| Institutional revenue | $1.758 million | $1.778 million | -1.1% |
| International revenue | $0.716 million | $0.713 million | +0.4% |
| Gross profit | $20.568 million | $17.876 million | +15.1% |
| Gross margin | 79.5% | 77.7% | +180 basis points |
| Operating income | $3.569 million | $3.109 million | +14.8% |
| Net income | $2.229 million | $2.213 million | +0.8% |
| Diluted EPS | $0.26 | $0.27 | Decrease |
| Cash provided by operations | $1.191 million | $2.167 million | Decrease |
SG&A increased 14.0% to $16.402 million, driven primarily by additional sales and administrative personnel, compensation, sales incentives, recruiting, travel and professional fees. R&D expense increased to $597,000 from $380,000, and approximately $223,000 was capitalized for SmartVest Connect software development.
At June 30, 2017, cash was $5.574 million, total current assets were $18.476 million and working capital was approximately $15.580 million. Accounts receivable increased to $9.950 million from $7.611 million, contributing to lower operating cash flow. Total debt was approximately $1.154 million, consisting primarily of the term loan; no balance was outstanding under the revolving line of credit.
The company had a $2.5 million revolving credit facility, subject to borrowing-base limitations, expiring December 18, 2017 if not renewed. The term loan bears interest at 3.88%, with approximately $1.085 million due at maturity in December 2018. Electromed was in compliance with its debt covenants at June 30, 2017.
Material Changes Versus the Prior Period
- Revenue growth was concentrated in domestic home-care sales, supported by increased referrals, approvals and average reimbursement rates.
- Fiscal 2017 included approximately $703,000 of net recognized revenue from a settlement with CMS involving approximately 700 Medicare claims from 2012–2015.
- Revenue was reduced by approximately $212,000 from repayment of previously collected amounts to a state Medicaid program following a change in that program’s reimbursement interpretation.
- Gross margin improved primarily because of higher home-care revenue and lower SmartVest SQL manufacturing costs.
- Operating expense growth largely offset the gross-profit improvement, leaving net income essentially flat.
- Cash from operations declined because accounts receivable increased by approximately $2.338 million and accounts payable and accrued liabilities decreased by approximately $337,000.
- Share-based compensation increased to $479,000 from $223,000.
- The company abandoned patents with a net value of approximately $133,000, compared with $18,000 in the prior year.
- The medical-device excise tax remained subject to a two-year moratorium, reducing fiscal 2017 expense by approximately $132,000 versus fiscal 2016.
Outlook, Risks and Unusual Items
Management’s fiscal 2018 goals were profitable growth, improved referral quality and reimbursement rates, and continued focus on integrity, respect and privacy. Planned initiatives included sales-force expansion, greater focus on adult pulmonology and bronchiectasis, broader payer coverage, improved therapy adherence, continued product innovation and increased institutional-market share.
Management indicated that long-term gross margins were expected to remain slightly above 75%, although short-term results could vary with reimbursement and referral mix. R&D spending was expected to remain relatively consistent as a percentage of revenue.
- Revenue depends substantially on Medicare, Medicaid and commercial insurance coverage and reimbursement rates. Actual collections may be below allowable amounts because of deductibles, co-payments, coverage limits and patient payment risk.
- The company relies on continued regulatory compliance, FDA clearances, international certifications and protection of its intellectual property.
- Competition includes Hill-Rom’s airway-clearance products, RespirTech’s inCourage System and International Biophysics’ AffloVest, as well as alternative pulmonary therapies.
- Failure to renew the revolving credit facility, breach of debt covenants or acceleration of secured debt could adversely affect liquidity and operations.
- Installment-method sales create collection and revenue-recognition uncertainty; approximately $1.814 million of estimated sales remained unrecognized at June 30, 2017.
- The company reported no material litigation, no off-balance-sheet arrangements and no material environmental impact expected from compliance.
- The independent auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; auditor attestation was not required because Electromed was a smaller reporting company.
Important Facts for Investors to Verify
- Whether the revolving credit facility was renewed after its December 18, 2017 expiration date and on what terms.
- Subsequent collection performance for the elevated accounts receivable balance and installment-method receivables.
- The recurring versus nonrecurring effects of the $703,000 CMS settlement and $212,000 Medicaid repayment.
- Whether SmartVest Connect and Aerobika generate material incremental revenue and improve patient adherence or reimbursement outcomes.
- Changes in Medicare, Medicaid and commercial payer coverage, allowable reimbursement rates and documentation requirements.
- Progress toward the company’s fiscal 2018 growth objectives, including sales-force expansion and adult pulmonology referrals.
- The effect of adopting the new revenue-recognition standard and any changes to deferred or installment-method revenue.
- Potential margin pressure from reimbursement mix, competition, regulatory actions, warranty obligations and the expiration of one U.S. patent during fiscal 2018.